ImmuCell director reports stock option holdings

ImmuCell Corp (ICCC) director Gilles Guillemette filed an initial Form 3 reporting stock option holdings.

Rhea-AI Filing Summary

ImmuCell Corp (ICCC) director Gilles Guillemette filed an initial Form 3 reporting stock option holdings. The filing shows non-qualified stock options to acquire 17,899 shares of common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.

The options vest in three equal annual installments: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares become exercisable on April 15, 2029. All reported holdings are owned directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Guillemette Gilles

Role Director

Type	Security	Shares	Price	Value
holding	Non Qualified Stock Options (Right to buy)	--	--	--

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 17,899 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.

Key Figures

Underlying option shares: 17,899 shares Exercise price: $7.60 per share Option expiration: April 15, 2036 +3 more

6 metrics

Underlying option shares 17,899 shares Non-qualified stock options to buy common stock

Exercise price $7.60 per share Strike price of reported stock options

Option expiration April 15, 2036 Expiry date of non-qualified stock options

First vesting tranche 5,966 shares Vesting on April 15, 2027

Second vesting tranche 5,966 shares Vesting on April 15, 2028

Final vesting tranche 5,967 shares Vesting on April 15, 2029

Key Terms

Non Qualified Stock Options, Form 3, exercise price, vesting

4 terms

Non Qualified Stock Options financial

"Non Qualified Stock Options (Right to buy)"

Form 3 regulatory

"Gilles Guillemette filed an initial Form 3 reporting stock option holdings"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

exercise price financial

"at an exercise price of $7.60 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests as follows: 5,966 shares becoming exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ImmuCell (ICCC) Form 3 filed by Gilles Guillemette report?

The Form 3 reports Gilles Guillemette’s initial ownership of non-qualified stock options in ImmuCell. These options cover 17,899 shares of common stock at a fixed exercise price and follow a multi-year vesting schedule, providing long-term equity-based compensation aligned with company performance.

How many ImmuCell (ICCC) shares are covered by Guillemette’s stock options?

Guillemette’s non-qualified stock options cover 17,899 shares of ImmuCell common stock. This number reflects the total underlying shares tied to the option grant, which becomes exercisable over time based on the stated vesting dates through April 15, 2029, if service conditions are satisfied.

What is the exercise price and expiration date of the ImmuCell (ICCC) options?

The options have an exercise price of $7.60 per share and expire on April 15, 2036. This means Guillemette can buy ImmuCell shares at $7.60 once vested, any time before expiration, subject to the company’s equity plan and applicable securities and insider trading rules.

How do the ImmuCell (ICCC) director’s options vest over time?

The stock options vest in three annual tranches. 5,966 shares become exercisable on April 15, 2027, another 5,966 on April 15, 2028, and 5,967 on April 15, 2029. This staggered vesting encourages multi-year board service and long-term alignment with shareholder interests.

Is the ImmuCell (ICCC) Form 3 a buy or sell transaction?

The Form 3 does not report a buy or sell transaction; it is an initial ownership filing. It simply discloses Guillemette’s existing non-qualified stock option grant and its terms, including the number of underlying shares, exercise price, vesting schedule, and expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 12:26 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Guillemette Gilles

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	(1)	04/15/2036	Common Stock	17,899	$7.6	D

Explanation of Responses:

1. The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)